Shenzhen Weiguang Biological Products Co Ltd (002880.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE100002Q58
Shenzhen Weiguang Biological Products Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.20 bn CNY | 1.27 bn CNY |
| Gross profit | 503.87 m CNY | 498.61 m CNY |
| Operating income | 296.62 m CNY | 324.00 m CNY |
| EBIT | 319.60 m CNY | 303.91 m CNY |
| Net income | 253.52 m CNY | 246.32 m CNY |
| Diluted EPS – continuing operations | 1.12 CNY | 1.09 CNY |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Shenzhen Weiguang Biological Products Co Ltd
Shenzhen Weiguang Biological Products Co., Ltd. engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection freeze-dried, lyophilized human rabies vaccine and human prothrombin complex. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 1985 and is based in Shenzhen, China.
More stocks
- Xingtong Shipping Co. Ltd. (603209.SS)
- Xuchang Yuandong Drive Shaft Co Ltd (002406.SZ)
- Shinyoung Securities Co. Ltd. (001720.KS)
- Silex Systems Ltd (SLX.AX)
- PARK OHIO HOLDINGS CORP (PKOH)
- T1 Energy Inc. (TE)
- SANFILIPPO JOHN B & SON INC (JBSS)
- Aclaris Therapeutics, Inc. (ACRS)
- Chicony Power Technology Co Ltd (6412.TW)
- Midland States Bancorp, Inc. (MSBI)
- Associated Capital Group, Inc. (ACGP)
- Ronglian Group Ltd (002642.SZ)
Not investment advice. All data without warranty, price as of 09.11.2026. Details in the risk notice.